Ocular Therapeutix Inc (NASDAQ: OCUL) kicked off on Monday, up 28.06% from the previous trading day, before settling in for the closing price of $12.58. Over the past 52 weeks, OCUL has traded in a range of $5.78-$13.85.
A company in the Healthcare sector has jumped its sales by 8.51% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -18.92%. With a float of $186.81 million, this company’s outstanding shares have now reached $213.05 million.
Ocular Therapeutix Inc (OCUL) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Ocular Therapeutix Inc is 12.31%, while institutional ownership is 79.23%. The most recent insider transaction that took place on Nov 24 ’25, was worth 22,611. In this transaction Chief Strategy Officer of this company sold 1,878 shares at a rate of $12.04, taking the stock ownership to the 277,860 shares. Before that another transaction happened on Nov 24 ’25, when Company’s insider sold 19,530 for $12.04, making the entire transaction worth $235,141. This insider now owns 3,157,960 shares in total.
Ocular Therapeutix Inc (OCUL) Latest Financial update
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -0.29 earnings per share (EPS), lower than consensus estimate (set at -0.22) by -0.07. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.34 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -18.92% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 4.86% during the next five years compared to 8.51% growth over the previous five years of trading.
Ocular Therapeutix Inc (NASDAQ: OCUL) Trading Performance Indicators
Take a look at Ocular Therapeutix Inc’s (OCUL) current performance indicators. Last quarter, stock had a quick ratio of 7.78. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 61.53.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.44, a number that is poised to hit -0.32 in the next quarter and is forecasted to reach -1.41 in one year’s time.
Technical Analysis of Ocular Therapeutix Inc (OCUL)
Let’s dig in a bit further. During the last 5-days, its volume was 6.02 million. That was better than the volume of 2.18 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 80.13%.
During the past 100 days, Ocular Therapeutix Inc’s (OCUL) raw stochastic average was set at 94.63%, which indicates a significant increase from 93.77% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.71 in the past 14 days, which was higher than the 0.60 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $11.71, while its 200-day Moving Average is $10.02. However, in the short run, Ocular Therapeutix Inc’s stock first resistance to watch stands at $16.84. Second resistance stands at $17.57. The third major resistance level sits at $18.70. If the price goes on to break the first support level at $14.98, it is likely to go to the next support level at $13.85. The third support level lies at $13.12 if the price breaches the second support level.
Ocular Therapeutix Inc (NASDAQ: OCUL) Key Stats
The company with the Market Capitalisation of 3.43 billion has total of 213,047K Shares Outstanding. Its annual sales at the moment are 63,720 K in contrast with the sum of -193,510 K annual income. Company’s last quarter sales were recorded 14,540 K and last quarter income was -69,420 K.
